Myotonic Dystrophy Clinical Trial Pipeline Boom As Over 20 Companies Leading The Charge In Research And Development Delveinsight
An increase in research and development (R&D) activities in myotonic dystrophy is expected to drive <a target=_blank href ...
Sarepta price target lowered to $202 from $205 at Needham
Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead (ARWR) offers platform diversification with clear long-term ...